{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:56:06Z","timestamp":1782262566864,"version":"3.54.5"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":273,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Nascent Biotech"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>This phase 1 (NCT04396717) open-label, multicenter study, evaluated Pritumumab, a IgG1 monoclonal antibody, in patients with gliomas and brain metastases. The primary objective was to evaluate the safety and\/or tolerability and to identify a recommended phase 2 dose (RP2D) of Pritumumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Adult patients with recurrent gliomas or brain metastases were enrolled in the dose cohort that was open at the time of their consent. Study treatment consisted of pritumumab administered intravenously weekly on days 1, 8, 15, and 22 in 28-day cycles. Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity were evaluated.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fifteen patients received Pritumumab in the recurrent setting. Pritumumab was well tolerated, with no serious adverse events related to Pritumumab reported. The most common drug-related toxicities were constipation and fatigue. There were no dose-limiting toxicities observed, and a maximum tolerable dose was not reached. Thus, the maximum feasible dose and recommended phase 2 dose of Pritumumab was established at 16.2 mg\/kg weekly. Out of eleven patients evaluated for efficacy, one patient (9.1%) demonstrated partial response based on response assessment in neuro-oncology criteria, and disease stabilization was seen in 3 patients (27.3%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Pritumumab was well tolerated with no DLTs observed up to 16.2 mg\/kg weekly. Further studies are warranted to determine clinical benefit in patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/noajnl\/vdae166","type":"journal-article","created":{"date-parts":[[2024,9,28]],"date-time":"2024-09-28T19:18:31Z","timestamp":1727551111000},"source":"Crossref","is-referenced-by-count":2,"title":["A phase 1 dose escalation of pritumumab in patients with refractory or recurrent gliomas or brain metastases"],"prefix":"10.1093","volume":"6","author":[{"given":"Jose","family":"Carrillo","sequence":"first","affiliation":[{"name":"Hoag Family Cancer Institute, Hoag Memorial Hospital , Newport Beach, California ,","place":["USA"]},{"name":"Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John\u2019s Cancer Institute at Providence Saint John\u2019s Health Center , Santa Monica, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3608-4392","authenticated-orcid":false,"given":"Jaya Mini","family":"Gill","sequence":"additional","affiliation":[{"name":"Nascent Biotech , North Palm Beach, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Redfern","sequence":"additional","affiliation":[{"name":"Sharp Clinical Oncology Research, Sharp Healthcare , San Diego, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Babic","sequence":"additional","affiliation":[{"name":"Gilman Biosciences , San Diego , California,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Nomura","sequence":"additional","affiliation":[{"name":"Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John\u2019s Cancer Institute at Providence Saint John\u2019s Health Center , Santa Monica, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval K","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University at Buffalo, The State University of New York , Buffalo, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Carrick","sequence":"additional","affiliation":[{"name":"Nascent Biotech , North Palm Beach, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3772-6000","authenticated-orcid":false,"given":"Santosh","family":"Kesari","sequence":"additional","affiliation":[{"name":"Department of Translational Neurosciences, Pacific Neuroscience Institute and Saint John\u2019s Cancer Institute at Providence Saint John\u2019s Health Center , Santa Monica, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"2024102507205808700_CIT0001","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noy131","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015","volume":"20","author":"Ostrom","year":"2018","journal-title":"Neuro Oncol."},{"issue":"5","key":"2024102507205808700_CIT0002","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","article-title":"Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial","volume":"10","author":"Stupp","year":"2009","journal-title":"Lancet Oncol."},{"issue":"11","key":"2024102507205808700_CIT0003","doi-asserted-by":"crossref","first-page":"e315","DOI":"10.1016\/S1470-2045(17)30194-8","article-title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol."},{"issue":"Suppl 5","key":"2024102507205808700_CIT0004","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/neuonc\/noz150","article-title":"CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016","volume":"21","author":"Ostrom","year":"2019","journal-title":"Neuro Oncol."},{"key":"2024102507205808700_CIT0005","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/neuonc\/not151","article-title":"CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010","volume":"15","author":"Ostrom","year":"2013","journal-title":"Neuro Oncol."},{"issue":"3","key":"2024102507205808700_CIT0006","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/cns.15.2","article-title":"Chemotherapy in glioma","volume":"4","author":"Taal","year":"2015","journal-title":"CNS Oncol."},{"issue":"5897","key":"2024102507205808700_CIT0007","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science."},{"issue":"6","key":"2024102507205808700_CIT0008","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"1","key":"2024102507205808700_CIT0009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12943-022-01513-z","article-title":"Glioma targeted therapy: Insight into future of molecular approaches","volume":"21","author":"Yang","year":"2022","journal-title":"Mol Cancer."},{"issue":"4","key":"2024102507205808700_CIT0010","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3233\/HAB-2009-0209","article-title":"Summary analysis of the pre-clinical and clinical results of brain tumor patients treated with pritumumab","volume":"18","author":"Glassy","year":"2009","journal-title":"Hum Antibodies."},{"issue":"2","key":"2024102507205808700_CIT0011","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3233\/HAB-2001-10204","article-title":"Determination of the antigen\/epitope that is recognized by human monoclonal antibody CLN-IgG","volume":"10","author":"Hagiwara","year":"2001","journal-title":"Hum Antibodies."},{"issue":"Suppl 19","key":"2024102507205808700_CIT0012","first-page":"318","article-title":"Use of the GPEx system to increase production of pritumumab in a CHO cell line","volume":"98","author":"Gupta","year":"2013","journal-title":"J Bioprocess Technol."},{"issue":"4","key":"2024102507205808700_CIT0013","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1442-200X.1987.tb02238.x","article-title":"Cytotoxicity of mixed human monoclonal antibodies reacting to tumor antigens","volume":"29","author":"Hagiwara","year":"1987","journal-title":"Acta Paediatr Jpn."},{"issue":"2","key":"2024102507205808700_CIT0014","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0304-3835(92)90190-7","article-title":"Antibody dependent cell mediated cytotoxicity on human cervical carcinoma cell line, ME-180, with human monoclonal antibody","volume":"62","author":"Osumi","year":"1992","journal-title":"Cancer Lett."},{"issue":"18","key":"2024102507205808700_CIT0015","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1007\/s00018-011-0735-1","article-title":"Vimentin in cancer and its potential as a molecular target for cancer therapy","volume":"68","author":"Satelli","year":"2011","journal-title":"Cell Mol Life Sci."},{"key":"2024102507205808700_CIT0016","article-title":"Analysis of hybridoma and CHO-derived pritumumab for therapeutic applications","volume":"35","author":"Ivan Babic","year":"2017","journal-title":"J Clin Oncol."},{"key":"2024102507205808700_CIT0017","first-page":"128","article-title":"Distribution and pharmacokinetics of human monoclonal antibody in nude mice implanted with malignant glioma cells","volume":"3","author":"Kokunai","year":"1990","journal-title":"Neuroimmunological Res."},{"key":"2024102507205808700_CIT0018","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/978-4-431-68150-2_65","article-title":"Antitumor effects of human monoclonal antibodies on human malignant glioma xenografts and their clinical application","volume-title":"Biol Aspects Brain Tumors.","author":"Tawamoto","year":"1991"}],"container-title":["Neuro-Oncology Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/noa\/advance-article-pdf\/doi\/10.1093\/noajnl\/vdae166\/59450867\/vdae166.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae166\/60075805\/vdae166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/noa\/article-pdf\/6\/1\/vdae166\/60075805\/vdae166.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:21:24Z","timestamp":1729840884000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/noa\/article\/doi\/10.1093\/noajnl\/vdae166\/7795944"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/noajnl\/vdae166","relation":{},"ISSN":["2632-2498"],"issn-type":[{"value":"2632-2498","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2024,1,1]]},"article-number":"vdae166"}}